Journal
NATURE REVIEWS CANCER
Volume 8, Issue 4, Pages 299-308Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2355
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [ZIABC010763, Z01BC010985, Z01SC003811, ZIABC010984, ZICBC011020, Z01SC003800] Funding Source: NIH RePORTER
- Intramural NIH HHS [Z01 SC003811-33] Funding Source: Medline
Ask authors/readers for more resources
Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available